


PHARMACEUTICAL 2017

XBiotech Inc. Rank 222 of 313







PHARMACEUTICAL 2017

XBiotech Inc. Rank 222 of 313



The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 158% points. The greatest weakness of XBiotech Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 263% points.

The company's Economic Capital Ratio, given in the ranking table, is -407%, being 9.1% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	36,930
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,963
Liabilities, Non-Current	0
Other Assets	19,978
Other Compr. Net Income	-1,781
Other Expenses	0
Other Liabilities	23
Other Net Income	2.0
Property and Equipment	10,142
Research and Development	42,486
Revenues	0
Selling, General and Administrative Expense	10,277

Output Variable	Value in 1000 USD
Assets	67,050
Liabilities	7,986
Expenses	52,763
Stockholders Equity	59,064
Net Income	-52,761
Comprehensive Net Income	-53,652
Economic Capital Ratio	-407%